Resources by Therapeutic Area

Resources by Therapeutic Area

LEXINGTON, MA – August 26, 2015 Quanterix Corporation, a leader in high definition diagnostics, today announced that The Journal of Clinical Chemistry has published a new study in which its single molecule array technology (Simoa) was used to measure cardiac troponin I (cTnI) levels with both high a…
Clinical Chemistry | August 17, 2015
The association between increases in cardiac troponin and adverse cardiac outcomes is well established. There is a growing interest in exploring routine cardiac troponin monitoring as a potential early indicator of adverse heart health trends. Prognostic use of cardiac troponin measurements requires…
2015 American Association for Clinical Chemistry
P. Patel , D. Shan , L. Styskal , L. Chang , D. H. Wilson , M. J. Conrad , P. Jarolim Quanterix Corporation, Lexington, MA, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Clinical Biochemistry | December 4, 2014
There is considerable clinical interest in the development and possible implementation of highly sensitive cardiac troponin I (cTnI) assays for early rule out of acute coronary syndromes, short-term (30 days) risk stratification for future adverse cardiac events, and for detecting cardiac injury amo…
Clinical Chemistry and Laboratory Medicine | October 22, 2014
Immunoassays measuring cardiac troponins I or T have become firmly established as critical tools for diagnosing acute myocardial infarction.